BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Friday announced alignment with the U.S. food and drug administration after a pre-submission meeting on the Helix transendocardial delivery catheter system. Helix was designed for the minimally invasive, targeted delivery of...
CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights. The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic...
Traws Pharma Inc. (TRAW), a clinical-stage biopharmaceutical company, on Friday announced plans to advance potential clinical candidates for the treatment and prevention of Hantavirus infections. Following the announcement, shares are up over 20% in the pre-market. Traws specializes in the manufacture...
Progyny Inc. (PGNY) reported on Thursday the first-quarter financial results and provided an updated outlook for the second quarter and full year 2026. The company specializes in providing women's health and family-building solutions, utilizing education and digital tools alongside a network of health...
This week's biotech roundup features the FDA's path forward for Atara's tab-cel, Arvinas' first-in-class PROTAC approval, and Incyte's Jakafi XR securing a regulatory nod. The week also saw Novartis announcing a site closure, Roche striking a $750 million PathAI deal, and Angelini agreeing to buy Catalyst...
Artiva Biotherapeutics, Inc. (ARTV) on Friday announced positive initial data from ongoing studies evaluating its cell therapy candidate AlloNK in combination with rituximab for patients with autoimmune diseases. The company's shares were up more than 10% in pre-market trading.
Pacific Biosciences of California Inc. (PACB), a life sciences technology company, on Thursday announced the first quarter financial results and provided updates on its business. The company designs, develops and manufactures gene sequencing technology, including sequencing systems, consumable products,...
Werewolf Therapeutics Inc. (HOWL), a biopharmaceutical company, on Thursday announced the first quarter financial results. The company specializes in developing conditionally activated therapies that stimulate the body's immune system to treat cancer and immune-mediated diseases. It has developed...
LeonaBio Inc. (LONA), a clinical-stage biopharmaceutical company, on Thursday released the first quarter financial results, and provided updates on its developing pipeline of drugs. Q1 2026: The company reported a net loss of $32.96 million, or $1.73 per share in Q1 2026, while in the same period...
Aligos Therapeuitcs, Inc. (ALGS) has reported first-quarter 2026 financial results, narrowing its net loss while advancing multiple clinical programs in liver and viral diseases.
LifeStance Health Group, Inc. (LFST) yesterday announced the pricing of a secondary underwritten public offering of 35 million shares of common stock at $8.15 per share. The offering, made by selling stockholders, is expected to generate gross proceeds of approximately $285 million for those holders, with LifeStance itself not receiving any proceeds.
Lyell Immunopharma Inc. (LYEL), a late-stage clinical company, released on Wednesday results from the first quarter, and provided updates on the developing pipeline of drug candidates. The company specializes in next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of...
Black Diamond Therapeutics, Inc. (BDTX), reported first-quarter 2026 financial results and provided a corporate update, underscoring continued progress across its MasterKey oncology pipeline, led by its fourth-generation EGFR inhibitor Silevertinib.
Clover Health Investments Corp. (CLOV), a physician-enabling technology company, on Wednesday reported first quarter financial results, and provided an outlook for 2026. Q1 2026: Clover recorded net revenues of $749.2 million in Q1 2026, 62.1% higher than the $462.3 million reported a year ago. The...
KORU Medical Systems, Inc. (KRMD), a medical technology company, reported financial results for the first quarter ended March 31, 2026, with 22% revenue growth. In addition, the firm reiterated its full-year 2026 guidance. Company Profile KORU Medical Systems develops, manufactures, and commercialises...
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.